Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ironwood Pharma Second Quarter Loss Widens, Revenue Slides

By Pharmaceutical Processing | July 23, 2013

Ironwood Pharmaceuticals Inc.’s second-quarter loss widened, as higher selling and collaboration expenses weighed on the drug developer, but the performance topped Wall Street expectations and shares rose on Tuesday trading.

The Cambridge, Mass., company said it lost $65.1 million, or 57 cents per share, in the three months that ended June 30. That compared with a loss of $40.8 million, or 38 cents per share, in last year’s quarter.

A 6-percent jump in the number of outstanding shares narrowed the loss on a per-share basis by 4 cents in the recent quarter.

Revenue slipped 34 percent to $9.7 million, from $14.6 million a year ago.

Analysts expected, on average, a loss of 68 cents per share on $8.2 million in revenue, according to FactSet.

Ironwood shares jumped 9 percent, or $1, to $12.08 in Tuesday morning trading.

The company said its total cost and expenses climbed 25 percent in the quarter to $69.5 million. Ironwood and its partner, Forest Laboratories Inc., are selling the bowel drug Linzess, which reached the market in December, and that has played a role in its jump in marketing costs.

The Food and Drug Administration approved Linzess to treat both irritable bowel syndrome with constipation and a form of chronic constipation in adults. Ironwood is working with Forest to sell the drug in the United States and receives half of the profit or bears half of the loss from that agreement.

Ironwood booked a net loss of $19.4 million in the quarter for the drug, which racked up heavy commercial expenses.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE